ISA Pharmaceuticals participates in newly-launched Tumor Neoantigen Selection Alliance (TESLA)

01 Dec 2016

ISA Pharmaceuticals participates in the newly-launched Tumor neoantigEn SeLection Alliance (TESLA), run by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). Read the full press release here:

http://www.parkerici.org/media/2016/parker-institute-for-cancer-immunotherapy-cri-neoantigen-alliance

Previous
Next